SG3 Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

SG3 Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,500	Closed	-$259K	–	38
2022 Q4	$259K	Buy	+2,500	New	+$235K	0.04%	148
2022 Q3	–	Sell	-10,300	Closed	-$917K	–	311
2022 Q2	$854K	Sell	10,300 -1,700	-14%	-$135K	0.1%	148
2022 Q1	$925K	Sell	12,000 -20,500	-63%	-$1.72M	0.03%	476
2021 Q4	$2.87M	Buy	32,500 +7,500	+30%	+$619K	0.06%	273
2021 Q3	$1.93M	Buy	25,000 +14,500	+138%	+$1.14M	0.06%	309
2021 Q2	$876K	Sell	10,500 -8,100	-44%	-$642K	0.03%	508
2021 Q1	$1.4M	Sell	18,600 -17,365	-48%	-$1.42M	0.04%	507
2020 Q4	$3.15M	Buy	+35,965	New	+$2.85M	0.06%	283

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SG3 Management's BMRN Position: Q1 2023 in Review

SG3 Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,500 shares — an estimated $259K sold.

SG3 Management first reported a position in BMRN in Q4 2020 and held it in 8 quarters. The position peaked at $3.15M in Q4 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

SG3 Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 2,500 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $259K.
SG3 Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 8 quarters.
SG3 Management's BioMarin Pharmaceuticals position peaked at $3.15M in Q4 2020.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.